PRIMARY STUDY
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS)
Key Findings: Looking at safety, tolerability, and preliminary effects this study finds that products containing cannabidiol, cannabigerol, beta-caryophyllene, branched-chain amino acids, or magnesium citrate reduced the delayed onset muscle soreness (DOMS) of performing daily activities, suggesting they may help in post-exercise recovery.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 40
Study Result: Positive
Study Location(s): Canada, United States
Year of Pub: 2023
Cannabinoids Studied: Cannabidiol (CBD), Cannabigerol (CBG), Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype III
Terpenes Studied: ß-Caryophyllene
DOSING DETAILS 
Study Dosing Objective: Effective Dose, Safety Profile
Established Protocol: Effective dose with adverse effects
Cannabinoid Ratio: (CBD : CBG) 35 : 50 
Dosage Form: cannabidiol(CBD; 35 mg) cannabigerol (CBG; 50 mg) beta-caryophyllene (BCP; 25 mg) branched-chain amino acids (BCAAs; 3.8 g) magnesium citrate (420 mg)
Dosing Regimen: Participants consumed the formulation twice per day
Treatment Duration: 3.5 days
Clinical Relevance: The tested formulation improved function and reduced interference of delayed onset muscle soreness on daily activities.
Adverse Events: One adverse event in the active group (diarrhea) and two in the placebo (dry mouth; eye rash/swollen eye).
Link to study
